


**SUPPORTING INFORMATION AVAILABLE**

**EPR and  $^{51}\text{V}$  NMR studies of prospective anti-diabetic *bis*(3-hydroxy-4-pyridinonato) oxidovanadium(IV) complexes in aqueous solution and liposome suspensions**


Sofia Ferreira<sup>a</sup>, Andreia Leite<sup>b\*</sup>, Tânia Moniz<sup>b</sup>, Mariana Andrade<sup>c</sup>, Luísa Amaral<sup>d</sup>, Baltazar de Castro<sup>b</sup>, Maria Rangel<sup>a\*</sup>

**TABLE OF CONTENTS:**


EPR spectra of $\text{VO}(\text{etpp})_2$ in MOPS and POPC along the time	2
$^{51}\text{V}$ NMR spectra of $\text{VO}(\text{etpp})_2$ in MOPS and POPC along the time	2
EPR spectra of $\text{VO}(\text{mepp})_2$ in MOPS and POPC along the time	3
$^{51}\text{V}$ NMR spectra of $\text{VO}(\text{mepp})_2$ in MOPS and POPC along the time	3
EPR spectra of $\text{VO}(\text{empp})_2$ in MOPS and POPC along the time	4
$^{51}\text{V}$ NMR spectra of $\text{VO}(\text{empp})_2$ in MOPS and POPC along the time	4




**Figure S1**- EPR spectra of  $\text{VO}(\text{etpp})_2$  in MOPS (left) and POPC (right) at 1.5 mM and at 0h (a); 1h (b); 2h(c) and 3h (d).




**Figure S2** –  $^{51}\text{V}$  NMR spectra of  $\text{VO}(\text{etpp})_2$  in MOPS (left) and POPC (right) at 1.5 mM and at 0h, 1h, 2h and 3h.




**Figure S3** - EPR spectra of  $\text{VO}(\text{mepp})_2$  in MOPS (left) and POPC (right) at 1.5 mM and at 0h (a); 1h (b); 2h(c) and 3h (d).



**Figure S4** -  $^{51}\text{V}$  NMR spectra of  $\text{VO}(\text{mepp})_2$  in MOPS (left) and POPC (right) at 1.5 mM and at 0h, 1h, 2h and 3h.



**Figure S5** - EPR spectra of  $\text{VO}(\text{empp})_2$  in MOPS (left) and POPC (right) at 1.5 mM and at 0h (a); 1h (b); 2h(c) and 3h (d).



**Figure S6** –  $^{51}\text{V}$  NMR spectra of  $\text{VO}(\text{empp})_2$  in MOPS (left) and POPC (right) at 1.5 mM and at 0h, 1h, 2h and 3h.